Epigenomics, Predictive Biosciences Extend Agreement on Prostate Cancer Dx | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Epigenomics and Predictive Biosciences today said that Predictive Biosciences will develop a prostate cancer test using the GSTP1 biomarker, under a licensing agreement extension.

The agreement, originally forged in 2009, gave Predictive the option to develop the test using the biomarker. In announcing today that it is executing that option, Predictive added that it will also commercialize the test. In return, Epigenomics will receive a one-time fee.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A Karmagenes researcher has lost his position after reportedly admitting to data fabrication, according to Retraction Watch.

Two neuroscientists write in Nature News that solving the "reproducibility crisis" in science may require changing the requirements for publication.

In Nature this week: genomic analysis of prehistoric New Mexicans, a nanopore method for mapping DNA methylation, and more.

A new study finds that adding missing good bacteria to the skin microbiome of atopic dermatitis patients decreases Staphylococcus aureus colonization.